VEGFA and pulmonary arterial hypertension: This hypothesis is supported by investigations reporting increased VEGF concentrations in SSc patients with systemic fibrosis, specific alterations in nailfold capillary density and patterns (31, 32), and well-established complications, e.g., pulmonary arterial hypertension (31, 33).